Glaucoma is a common eye condition that affects millions of individuals worldwide, making it
the second-leading cause of blindness. Because glaucoma is associated with increased IOP …

The armamentarium for the medical treatment of glaucoma recently experienced an
unprecedented expansion of available agents. Years ago, the choice was limited to miotics …

Background Therapy for the glaucomas is dynamic, with changes evolving as new
medications or modalities are discovered. In comparing the method (s) of treating open …

Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma
consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent …

The goals of glaucoma therapy for the patient and the physician are ultimately the same
ones, but they are often approached from very different perspectives. Most patients with …

Although challenges in medical treatment of glaucoma exist, particularly in patient
adherence, medical therapy remains the first line treatment for almost all glaucoma patients …

Today, clinicians have unprecedented versatility in the treatment of glaucoma. Early
detection, prevention, and control are promises inherent in the expansion of the …

For some time the medical treatment of glaucoma has consisted of topical β-blockers,
adrenergic agents, miotics and oral carbonic anhydrase inhibitors (CAIs). However, the …

New options in treatment are opening up for the 3 million Americans over age 39 who have
been diagnosed with glaucoma. Nevertheless, glaucoma remains a leading cause of …

Introduction: Glaucoma is the second leading cause of blindness in the world and current
pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of …